Literature DB >> 10491203

Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.

M G Juarranz1, J Van Rampelbergh, P Gourlet, P De Neef, J Cnudde, P Robberecht, M Waelbroeck.   

Abstract

In order to identify the receptor domains responsible for the VPAC1 selectivity of the VIP1 agonist, [Lys15, Arg16, Leu27] VIP (1-7)/GRF (8-27) and VIP1 antagonist, Ac His1 [D-Phe2, Lys15, Arg16, Leu27] VIP (3-7)/GRF (8-27), we evaluated their binding and functional properties on chimeric VPAC1/VPAC2 receptors. Our results suggest that the N-terminal extracellular domain is responsible for the selectivity of the VIP1 antagonist. Selective recognition of the VIP1 agonist was supported by a larger receptor area: in addition to the N-terminal domain, the first extracellular loop, as well as additional determinants in the distal part of the VPAC1 receptor were involved. Furthermore, these additional domains were critical for an efficient receptor activation, as replacement of EC1 in VPAC1 by its counter part in the VPAC2 receptor markedly reduced the maximal response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491203     DOI: 10.1046/j.1432-1327.1999.00769.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.

Authors:  J Perret; P Vertongen; R M Solano; I Langer; J Cnudde; P Robberecht; M Waelbroeck
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

2.  Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.

Authors:  Ingrid Nachtergael; Pascale Vertongen; Ingrid Langer; Jason Perret; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

Authors:  J Van Rampelbergh; M G Juarranz; J Perret; A Bondue; R M Solano; C Delporte; P De Neef; P Robberecht; M Waelbroeck
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

5.  Development by Genetic Immunization of Monovalent Antibodies Against Human Vasoactive Intestinal Peptide Receptor 1 (VPAC1), New Innovative, and Versatile Tools to Study VPAC1 Receptor Function.

Authors:  Xavier Peyrassol; Toon Laeremans; Vannessa Lahura; Maja Debulpaep; Hassan El Hassan; Jan Steyaert; Marc Parmentier; Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-05       Impact factor: 5.555

Review 6.  An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.

Authors:  Rosa P Gomariz; Yasmina Juarranz; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; Isidoro González-Álvaro; Irene Gutiérrez-Cañas; Amalia Lamana; Carmen Martínez
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-22       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.